In February 2016, Tara Wilkes left her job as a decorator and furniture sales associate, locked the door of her second home on Lake Waccamaw and moved back inland to the family home in Rockingham, North Carolina.
“I just couldn’t do my job,” said Wilkes, a petite and active 56-year-old grandmother of four. “I was tired, really tired -- and there was the swelling. I could no longer wear my rings, and my shoulder hurt.”
Wilkes had been the picture of health and vitality just a few months before, when she and her husband Neal, a businessman who’s often traveling, got a break from their busy schedules for a hiking getaway in the Georgia mountains.
Wilkes attributed the swelling to walking the 40,000-square-foot showroom, daily, and she figured she’d pulled her rotator cuff carrying heavy fabrics up and down the stairs of her clients’ coastal homes. Her local physician didn’t find anything wrong with her shoulder.
However, a trip to the emergency room when she turned jaundiced during a shopping trip, led to the eventual discovery of a tumor in her pancreas. An astute doctor connected her shoulder pain to a possible gallbladder problem and ordered an endoscopy — a nonsurgical procedure used to examine the digestive tract. Her gallbladder as it turned out, was indeed damaged, due to the pancreatic tumor nearby pressing against it.
Wilkes was referred to Duke surgeon Sabino Zani Jr., MD, and oncologist Niharika Mettu, MD, PhD. She underwent five-and-a-half weeks of radiation and chemotherapy, and in June that year had the Whipple procedure (a pancreaticoduodenectomy), in which the head of the pancreas is removed along with a portion of the bile duct, gallbladder, and the first portion of the small intestine. After undergoing 12 once-a-week intravenous chemotherapy treatments following surgery, and just in time for Christmas 2016, Wilkes was declared cancer free. Healthy again, she made a photo from that 2015 Georgia hiking trip into that year’s Christmas card.
Climbing the Charts
Located behind the stomach, the pancreas has both endocrine and exocrine functions; making a number of important proteins including insulin and digestive enzymes.
According to the National Cancer Institute, risk factors associated with pancreatic cancer include smoking, being very overweight, having a personal history of diabetes or chronic pancreatitis, having a family history of pancreatic cancer or pancreatitis, and having certain other hereditary conditions.
At this time, there are no guidelines that recommend pancreatic screening for those who harbor any of the personal medical history related risk factors and no guidelines that recommend pancreatic cancer screening for the general population. There is a consensus at Duke to consider screening patients with familial clusters of pancreatic cancer or those with hereditary genetic mutations that predispose the family to higher rates of pancreatic cancer. (READ MORE ABOUT SCREENING AT DUKE)
Pancreatic cancer is a rare, but highly morbid disease, accounting for just 3.2 percent of all new cancer cases, but 7.2 percent of all cancer deaths. The American Cancer Society projected there would be 53,670 new cases in the U.S. in 2017 and 43,090 deaths (final figures are not yet available).
Deaths are projected to increase to more than 60,000 per year by 2030, according to authors of a paper published in Cancer Research, which will make pancreatic cancer the second leading cause of cancer-related deaths after lung cancer — surpassing liver, breast, prostate, and colorectal cancers in mortality.
“This rise is, in part, secondary to decreased cancer-related deaths associated with breast, prostate and colorectal cancers but is also due to the aging of the American population,” said Duke Cancer Institute surgical oncologist Dan Blazer III, MD.
It’s an aggressive malignancy, noted Blazer, explaining that even in patients where surgical resection is possible, long-term survival is not achieved in the majority of patients, though outcomes have improved over the last decade.
According to the National Cancer Institute, the five-year survival rate for those with advanced disease is less than 10 percent — currently the worst five-year survival rate of all solid-organ malignancies.
“Our ability to cure that cancer is still pretty limited, despite improvements in surgical outcomes and systemic chemotherapy, so as the number of new cases go up, the deaths are going to go up,” said Blazer.
Because most symptoms of pancreatic cancer are non-specific — including weight loss, vague abdominal discomfort, change in stool color or consistency — the majority of pancreatic cancer patients already have advanced or metastatic disease when they are diagnosed. Depending on if they take and respond well to chemotherapy, metastatic patients have an average expected survival of between four months and a year.
Wilkes was fortunate that her tumor was identified early, explained her physician Mettu, when surgery was still possible. Only about 15 to 20 percent of patients, said Blazer, qualify for surgery. Typically, surgery is an option only if the pancreatic cancer is limited to the pancreas, has not metastasized to other organs and has not locally advanced to the point of encasing local regional blood vessels. However, at Duke and other select centers, in patients who are not surgically resectable by classic criteria, locally ablative therapies such as irreversible electroporation (IRE) may also be used, a novel strategy, said Blazer, to improve the numbers of patients who may be eligible for surgery.
Those who’ve had no form of chemotherapy or radiation therapy before surgery, have an average survival between 18 and 24 months. There’s a longer average survival — 30 to 35 months — in patients for whom chemotherapy and radiation taken ahead of surgery has either shrunk their tumor or stopped their cancer from progressing.
“You’ll see a definite improvement in those folks,” said Blazer.
However, Blazer explained that surgery doesn’t come without complications. While the operative mortality rate for the most common surgery, the Whipple, is less than two percent at high-volume institutions, including Duke, around 30 to 50 percent of patients will likely have some sort of complication after the procedure, ranging from minor to serious. If the tumor is in the body or tail of the pancreas, then a distal pancreatectomy, in which the pancreas and spleen are removed en bloc, may be an option. That procedure, Blazer said, is “less risky than the Whipple” and is “usually a pretty well tolerated procedure with fewer complications.”
Dolly Dunnagan, like Tara Wilkes, didn’t see it coming when she was diagnosed with pancreatic cancer in September 2014, but jaundice and extreme fatigue warranted a doctor visit. (Neither Dunnagan nor Wilkes had any of the personal risk factors or a family history or genetic connection to the disease.)
While Dunnagan had lost about 10 pounds over the summer, she chalked it up to long hours gardening at the family beach house on Harker’s Island. Then 67 years old, the grandmother of two was surprised by the diagnosis. Standard-of-care radiation and chemotherapy was followed by surgery at Duke in January 2015.
After four months of chemotherapy, Dunnagan was cleared of cancer, but last year a scan showed a couple of suspicious spots on Dolly’s lymph and the cancer antigen levels in her blood began to rise. Biopsies turned up negative.
Dunnagan and her physician Mettu continue close surveillance for her cancer, which consists of labs, imaging, and clinic visits every few months.
“We’re just playing a wait and see game right now,” said Dunnagan, who enjoys fishing on the weekends with her husband of 52 years.
“We’ve made some headway with pancreatic cancer treatment for all stages of pancreatic cancer,” said Mettu, while acknowledging that it’s an uphill climb.
In the last 10 years, several single agents and combinations of chemotherapies have been approved for the treatment of patients with metastatic pancreatic cancer — that can extend survival from four months up to six, eight, or 11.5 months.
“We’re still talking about improvements in life expectancy, with chemotherapy, measured in incremental numbers of months,” cautioned Mettu, explaining that it’s difficult for drugs to penetrate the organ’s complex microenvironment and kills the cancer cells. “What we need are regimens that are going to lead to responses that are durable, or that last a long time, like in breast cancer. I think the longer I do this, the more I realize that aiming for a cure may not be possible but aiming for long-term disease control is very reasonable.”
Immunotherapies, which are approved for the treatment of several cancers and have led to durable responses in other cancers, have not been shown to work for pancreatic cancer patients, at least as single agents, but studies of treatment regimens that utilize a combination of different checkpoint inhibitors or a combination of immunotherapy and chemotherapy drugs have been and are currently being conducted, including at Duke.
“Whenever possible, clinical trials are highly recommended for metastatic pancreatic cancer patients, since survival is still not optimal,” explained Mettu. “A good clinical trial is probably better than sticking with standard of care as it will further our understanding of how to treat this terrible disease and help to improve outcomes for patients by improving both quantity and quality of life for patients with pancreatic cancer.”
A Happy Holiday
Tara Wilkes, now a pancreatic cancer survivor, has spent the past year doing what she loves, including going to the beach, taking walks, playing with her grandchildren, visiting elderly shut-ins, restoring furniture, and painting. She painted a giant sunflower onto a barn door on her property, and hand-painted pillows and oven mitts as Christmas gifts for the family and friends that have taken care of her and prayed with her through her cancer “ordeal.” She and her husband Neal hosted a Christmas party at their house this year.
“I’m doing great,”she said. “One of the things that Dr. Mettu said to me, when I was cleared, was that it was time to start living my life again.”
“Both Tara and Dolly have done well, so may well do better than average,” reflected Mettu. “I am always inspired by the optimism of my patients with pancreatic cancer; so many of my patients find the ability to make the best of this situation and are very much invested in helping to further our treatments for this disease by participating in research that will move the needle forward in pancreatic cancer.”
Here’s a list of clinical trials currently open at Duke for pancreatic cancer:
- SWOG S1505: A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
- A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen
- Alliance A021501: Preoperative Extended Chemotherapy versus Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
For questions about enrolling and more details, call the research nurse at 919.668.1861.
Circle photo (top): Pancreatic cancer survivor Tara Wilkes in Orange Beach, Alabama, October 2017.